论文部分内容阅读
目的探讨自体DC-CIK细胞过继治疗复发难治性多发性骨髓瘤的临床疗效。方法体外扩增自体DC-CIK细胞,过继回输治疗21例复发难治性多发性骨髓瘤患者。结果治疗完成后,CR 1例(4.8%),PR 5例(23.8%),MR 9例(42.9%),PD6例(28.6%),总体有效率(CR+PR+MR)为71.4%;不良反应以寒战、低热和皮疹为主,对症处理后均得以缓解。结论自体DC-CIK细胞过继治疗复发难治性MM疗效明显,耐受性好,值得临床推广。
Objective To investigate the clinical efficacy of autologous DC-CIK cell adoptive therapy in relapse-refractory multiple myeloma. Methods In vitro expansion of autologous DC-CIK cells, adoptive transfer of 21 patients with refractory multiple myeloma. Results After treatment, 1 case (4.8%) was CR, 5 cases (23.8%) were PR, 9 cases (42.9%) were PD, 6 cases were PD (28.6%) and the total effective rate was 71.4% Adverse reactions to chills, fever and rash-based, symptomatic treatment were alleviated. Conclusion The adoptive treatment of autologous DC-CIK cells in relapsed and refractory MM has obvious curative effect and good tolerance, which is worthy of clinical promotion.